WAVE Life Sciences Added to the Russell 2000® Index

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, today announced that it has been added to the Russell 2000®, Russell 3000®, Russell Microcap® and the Russell Global® Indexes following this year’s Russell Indexes Reconstitution, effective as of June 27, 2016.

The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000®, representing approximately 10% of the total market capitalization of that index. Membership in the Russell 2000® Index includes automatic inclusion in the appropriate growth and style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. FTSE Russell determines membership for each index based on objective market capitalization rankings and style attributes.

About WAVE Life Sciences

At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com and follow us on Twitter at @WAVELifeSci and LinkedIn.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160627006444/en/

Investor Contact:
Westwicke Partners
Chris Brinzey, 339-970-2843
[email protected]
or
Media Contact:
Feinstein Kean Healthcare
Jess Rowlands, 202-729-4089
[email protected]

Source: WAVE Life Sciences

You May Also Be Interested In

• Cascades announces notice of partial redemption for its 5.375% senior notes due 2028
• CREMX Completes Latest Quarterly Repurchase Offer Following Three-Year Anniversary and Expanded Platform Access
• K2view positioned as a Leader in the SPARK Matrix™: Data Masking, Tokenization, and Synthetic Data Solutions, 2026 by QKS Group